E-viri
Recenzirano
-
Zhu, Yu; Li, Chen; Chen, Liming; Liu, Haiyan; Ou, Lun; Li, Tong; Wang, Xuan; Wang, Tenghua; Tian, Jingyuan; Liang, Xintong; Hu, Zhiqin; Zhan, Yaoxuan; Xiao, Shuangshuang; Wang, Xiaole; Li, Yongmei; He, Jin; Zheng, Qingshan; Song, Haifeng; Li, Xianbo; Fang, Yi
European journal of drug metabolism and pharmacokinetics, 05/2024, Letnik: 49, Številka: 3Journal Article
Background and Objective GB221 is a recombinant humanized anti-HER2 monoclonal antibody. The purpose of this study was to evaluate the pharmacokinetic, safety, and immunogenicity of GB221 in healthy Chinese adults in comparison to trastuzumab (Herceptin ® ). Methods In this randomized, double-blind, parallel-group phase I clinical trial, 88 subjects were randomized 1:1 to receive a single intravenous infusion (90-100 min) of GB221 or trastuzumab (6 mg/kg). The primary pharmacokinetic parameters—maximum observed serum concentration ( C max ), area under the serum concentration–time curve from zero to the last quantifiable concentration at time t (AUC 0– t ), and area under the serum concentration–time curve from time zero to infinity (AUC 0–∞ )—of GB221 and trastuzumab were compared to establish whether the 90% confidence interval (CI) attained the 80–125% bioequivalence standard. Safety and immunogenicity were also evaluated. Results The GB221 group ( n = 43) and the trastuzumab group ( n = 44) showed similar pharmacokinetic characteristics. The geometric mean ratios (90% CI) of C max , AUC 0– t , and AUC 0–∞ between the two groups were 107.53% (102.25–113.07%), 108.31% (103.57–113.26%), and 108.34% (103.57–113.33%), respectively. The incidence of treatment-emergent adverse events (TEAEs) was 83.7% (36/43) of the subjects in the GB221 group and 95.5% (42/44) of the subjects in the trastuzumab group. No subjects withdrew from the trial due to TEAEs, and there were no occurrences of serious adverse events. All subjects tested negative for antidrug antibodies (ADA). Conclusion GB221 demonstrated similar pharmacokinetics to trastuzumab and comparable safety and immunogenicity in healthy Chinese adults.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.